SecBot SecBot
8-K ·Filed Apr 3, 2026

INDP

Indaptus Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed7mo ago SEC0001493152-26-015079
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for future disclosures on Yu Ding's capital strategy given the company's $4M market cap and likely funding needs; watch for potential Asia-focused partnerships or financings given new executives' regional expertise

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.75
T+0 close · Apr 3, 2026 · via day close
Latest settled
+68.00%
T+60 · $2.94
Vs SPY
+54.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $1.75entry
  2. T+1 · 7mo ago −8.57%α −8.63% · $1.60
  3. T+5 · 7mo ago +17.71%α +13.58% · $2.06
  4. T+20 · 7mo ago +22.86%α +13.87% · $2.15
  5. T+60 · 5mo ago +68.00%α +54.53% · $2.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Indaptus Therapeutics announced the resignation of CFO Nir Sassi and the immediate appointment of Yu Ding as new CFO, along with the appointment of Qinglai Lu to the Board and Audit Committee. The leadership changes appear planned, with no disclosed disagreements, and bring fresh financial and Asia-Pacific market expertise to the company.

Key Facts

  • CFO Nir Sassi resigned effective April 1, 2026, with no disclosed disagreement with the company
  • Yu Ding appointed as new CFO effective immediately, bringing 20+ years of experience from CFO roles at Shanghai and Hong Kong-listed auto firms
  • Qinglai Lu appointed to Board of Directors (effective April 8, 2026) and Audit Committee, with extensive finance and Web3 investment experience in Asia-Pacific
  • Matthew McMurdo resigned from Audit Committee concurrent with Lu's appointment
  • No compensation details or employment agreements filed with this 8-K

Financial Impact

No immediate financial impact disclosed; leadership transition may influence future capital raising and Asia strategy

debtdilution

Risk Factors

  • Execution risk during CFO transition at a micro-cap biotech with limited resources
  • Potential distraction from R&D priorities during leadership change
  • No immediate insight into compensation costs for new executives

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-015079
Document: 0001493152-26-015079-index-headers.html0001493152-26-015079
Document: 0001493152-26-015079-index.html0001493152-26-015079
Document: 0001493152-26-015079.txt0001493152-26-015079

Track record

20 reports on INDP

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026